Fulton Bank N.A. Decreases Stake in Avantor, Inc. (NYSE:AVTR)

Fulton Bank N.A. lowered its holdings in Avantor, Inc. (NYSE:AVTR) by 15.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,272 shares of the company’s stock after selling 2,307 shares during the quarter. Fulton Bank N.A.’s holdings in Avantor were worth $260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Versant Capital Management Inc increased its position in Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares during the last quarter. Fifth Third Bancorp increased its position in Avantor by 125.3% in the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock worth $28,000 after buying an additional 694 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in Avantor by 565.5% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after buying an additional 1,131 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Avantor in the fourth quarter worth about $42,000. Finally, Montag A & Associates Inc. purchased a new stake in shares of Avantor during the fourth quarter worth about $43,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

AVTR has been the subject of several research analyst reports. TD Cowen increased their target price on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Stifel Nicolaus increased their target price on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of Avantor in a research report on Monday, July 29th. Barclays increased their target price on Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Finally, Morgan Stanley increased their target price on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.21.

Avantor Price Performance

NYSE AVTR traded up $0.21 during trading on Tuesday, hitting $25.16. 6,757,728 shares of the stock traded hands, compared to its average volume of 7,127,365. The company has a market capitalization of $17.10 billion, a P/E ratio of 64.50, a price-to-earnings-growth ratio of 2.71 and a beta of 1.32. The firm has a 50-day simple moving average of $22.61 and a 200-day simple moving average of $23.83. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. Avantor, Inc. has a 12-month low of $16.63 and a 12-month high of $28.00.

Insider Buying and Selling at Avantor

In other Avantor news, insider Christophe Couturier 10,000 shares of the company’s stock in a transaction on Tuesday, July 30th. The was disclosed in a document filed with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by company insiders.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.